Home Constitutions Bill of Rights Advocacy: Federal & State IVERMECTIN And FENBENDAZOLE Testimonials: Stage 2 Fallopian Tube Cancer, Stage 4 Breast Cancer With Lymph Node And Bone Metastases, 3 Months To Live Stomach Tumor

IVERMECTIN And FENBENDAZOLE Testimonials: Stage 2 Fallopian Tube Cancer, Stage 4 Breast Cancer With Lymph Node And Bone Metastases, 3 Months To Live Stomach Tumor

The first case involved the administration of the dubious and dangerous chemotherapy “treatment” combined with Ivermectin and Fenbendazole, and we can be all but certain that the only reason the patient is now in full remission is strictly due to the miraculous synergistic repurposed drugs:

by USA Citizens Network
0 comment

IVERMECTIN And FENBENDAZOLE Testimonials: Stage 2 Fallopian Tube Cancer, Stage 4 Breast Cancer With Lymph Node And Bone Metastases, 3 Months To Live Stomach Tumor

 

Discussion about this post

I have put in an order for Petmectin for my large dog that weighs the exact same as me. Let’s see if it is delivered from the US.

Reply
Share

Anticancer Potential of Repurposed Drugs and Natural Compounds: A Focus on Ivermectin, Fenbendazole, Quercetin, Vitamins C and D3, and Curcumin

By Sid Belzberg

Introduction

In the evolving landscape of anticancer therapies, the search for novel agents often uncovers unexpected candidates. Among these are drugs like Ivermectin and Fenbendazole, primarily used as antiparasitics, along with naturally occurring substances such as Quercetin, Vitamins C and D3, and Curcumin. Intriguingly, these compounds have demonstrated anticancer properties in vitro and in vivo, but the path to human trials has been slow and challenging, largely due to economic considerations in the repurposing of patent-expired drugs and natural compounds.

Repurposed Drugs and Natural Compounds as Anticancer Agents

Both Ivermectin and Fenbendazole have shown anticancer potential in preclinical studies, with reported effects including cytotoxicity to cancer cells and inhibition of tumor growth. The mechanisms underlying these effects appear to involve disruption of critical cellular processes, leading to cancer cell death.

Similarly, certain flavonoids and vitamins have shown promising anticancer properties. Quercetin, a flavonoid found in many fruits and vegetables, exhibits antioxidant, anti-inflammatory, and antiproliferative activities that can potentially inhibit cancer progression. Vitamins C and D3 have also shown anticancer potential, with Vitamin C inducing oxidative stress in cancer cells, and Vitamin D3 modulating cellular growth and differentiation. Curcumin, the active component of turmeric, has also demonstrated broad anticancer effects, potentially impacting multiple signaling pathways involved in cancer.

Economic Challenges in Drug and Natural Compound Repurposing

Despite these encouraging findings, the progression towards clinical trials for these compounds as anticancer treatments has been hindered. This slow pace can be attributed largely to economic constraints. Developing or repurposing a drug is a high-cost, time-intensive process, with clinical trials alone demanding significant financial and human resources.

For Ivermectin and Fenbendazole, their status as off-patent drugs allows production by multiple manufacturers, reducing the potential for return on investment for companies funding research into their anticancer uses. For natural compounds like Quercetin, Vitamins C and D3, and Curcumin, the inability to patent these substances similarly lowers the financial incentive for pharmaceutical companies to invest in extensive research and development.

The Case for Drug and Natural Compound Repurposing

Despite these challenges, the repurposing of these compounds carries potential advantages that justify further exploration. Since the safety and pharmacokinetic profiles of these substances are well-known, their development as anticancer agents could be faster and less expensive than for new drugs. Furthermore, the successful repurposing of these compounds could provide a cost-effective way to expand anticancer treatments, possibly improving patient outcomes while reducing healthcare costs.

Conclusion

While the economic aspects of drug development are a crucial consideration, they should not impede the pursuit of potential life-saving treatments. The cases of Ivermectin, Fenbendazole, Quercetin, Vitamins C and D3, and Curcumin highlight the need for alternative funding models and regulatory strategies to support the repurposing of off-patent drugs and natural compounds. Potential solutions could include public-private partnerships, non-profit or government funding, modifications to patent laws, or innovative models of drug development. By exploring such alternatives, we can ensure that the potential therapeutic benefits of these compounds are fully explored and capitalized on, irrespective of their economic attractiveness to pharmaceutical companies.

References

1 Caly, L., Druce, J.D., Catton, M.G., Jans, D.A., & Wagstaff, K.M. (2020). The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Research, 178, 104787.

2 Pourgholami, M.H., Khachigian, L.M., Fahmy, R.G., Badar, S., Wang, L., Chu, S.W., et al. (2010). Albendazole inhibits endothelial cell migration, tube formation, vasopermeability, VEGF receptor-2 expression and suppresses retinal neovascularization in ROP model of angiogenesis. Biochemical and Biophysical Research Communications, 397(4), 729-734.

3 Granja, A., Pinheiro, M., Reis, S. (2020). Epigallocatechin Gallate Nanodelivery Systems for Cancer Therapy. Nutrients, 8(5), 307.

4 Padayatty, S.J., Sun, A.Y., Chen, Q., Espey, M.G., Drisko, J., & Levine, M. (2010). Vitamin C: Intravenous Use by Complementary and Alternative Medicine Practitioners and Adverse Effects. PLoS ONE, 5(7), e11414.

5 Garland, C.F., & Garland, F.C. (1980). Do sunlight and vitamin D reduce the likelihood of colon cancer? International Journal of Epidemiology, 9(3), 227-231.

6 Hatcher, H., Planalp, R., Cho, J., Torti, F.M., & Torti, S.V. (2008). Curcumin: From ancient medicine to current clinical trials. Cellular and Molecular Life Sciences, 65(11), 1631-1652.

7. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5835698/. Mandy Juarez,1 Alejandro Schcolnik-Cabrera,1 and Alfonso Dueñas-Gonzalez2 The multitargeted drug ivermectin: from an antiparasitic agent to a repositioned cancer drug

Expand full comment
Reply
Share

12 more comments…

Share This

You May Also Like

Leave a Comment

This website uses cookies to improve your experience. We'll assume you're OK with this, but you can opt-out if you wish. Accept Read More